Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...

BioNTech CEO and co-founder Professor Ugur Sahin said: "We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional check ...

BioNTech said that with Pfizer ... and have made numerous clinical advances,” said Chief Executive Ugur Sahin. “Today, our oncology pipeline encompasses multiple candidates in mid- and ...

She has a Neutral rating and price target of $110. BioNTech’s founders, Ugur Sahin, the CEO, and his wife, Ozlem Tureci, the ...

Run by husband-and-wife team Ugur Sahin and his wife Ozlem Tureci, BioNTech wanted to use the technology to create individualised cancer therapies. Matthias Kromayer, a general partner at the ...

Commenting on the acquisition, Dr. Ugur Sahin, CEO of BioNTech said, "We are excited to welcome Biotheus and its innovative technology to BioNTech,". He further added, "This acquisition enhances ...

Co-infections, as well as consecutive respiratory infection during this period, can further increase the risk of severe illness,” said Professor Ugur Sahin, BioNTech’s chief executive.

“We see a significant opportunity at the intersection of AI and immunology by computational design of new precision immunotherapies,” said BioNTech chief executive Ugur Sahin. “This ...

BioNTech CEO'su Prof. Dr. Uğur Şahin, kanser aşısı için tarih verdi. Peki beklenen aşı ne zaman onaylanacak? İşte ayrıntılar! BioNTech'in kurucu ortağı ve Üst Yöneticisi (CEO) Prof. Dr. Uğur Şahin, ...

"The response to the pandemic has shown that science and innovation can transform people's lives when all key stakeholders work together towards a common goal," said BioNTech CEO Ugur Sahin.

BioNTech SE operates as immunotherapy company ... The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.